CC-5079: A Small Molecule with MKP1, Antiangiogenic, and Antitumor Activity
Authors:
- Huan N. VuHVHuan N. Vu
- Walter J. MillerWMWalter J. Miller
- Sarah A. O'COnnorSOSarah A. O'COnnor
- Mei HeMHMei He
- Peter H. SchaferPSPeter H. Schafer
- Faribourz PayvandiFPFaribourz Payvandi
- George W. MullerGMGeorge W. Muller
- David I. StirlingDSDavid I. Stirling
- Steven K. LibuttiSLSteven K. Libutti
- 1 November 2010
- journal article
- research article
- Published by Elsevier in Journal of Surgical Research
- Vol. 164 (1) , 116-125
Abstract
No abstract availableKeywords
Funding Information
- Celgene
- National Cancer Institute
- National Institutes of Health
This publication has 14 references indexed in Scilit:
- The Synthetic Compound CC-5079 Is a Potent Inhibitor of Tubulin Polymerization and Tumor Necrosis Factor-α Production with Antitumor ActivityCancer Research, 2006
- Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- The next generation of PDE4 inhibitorsCurrent Opinion in Chemical Biology, 2001
- Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitorsImmunopharmacology, 2000
- Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functionsCurrent Opinion in Cell Biology, 2000
- Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell DeathJournal of Clinical Oncology, 1999
- Tubulin as a target for anticancer drugs: Agents which interact with the mitotic spindleMedicinal Research Reviews, 1998
- Phosphodiesterase Isozymes: Molecular Targets for Novel Antiasthma AgentsAmerican Journal of Respiratory and Critical Care Medicine, 1998
- Anti-AngiogenesisAnnals of Surgery, 1972